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Patients and Methods
Information sources were searched for blinded randomised controlled trials (RCTs), of ≥2 weeks duration, comparing any dose of onabotulinumtoxinA, eligible oral/transdermal anticholinergics, or mirabegron, with each other or placebo, in adults with OAB. Bayesian random-effects models were used to synthesise the results at week 12: NMA for responder analyses and network meta-regression (NMR) for change from baseline analyses. The NMR was used to adjust for differences in baseline severity between studies. Sensitivity analysis, excluding studies considered to be at a high risk of methodological bias, was conducted.
Results
In all, 56 RCTs were included in the networks. For each outcome, results are reported for all licensed treatment doses. For each NMR, results are based on patients with an average number of episodes of the outcome at baseline. After 12 weeks, all treatments were more efficacious than placebo.
Patients who received onabotulinumtoxinA (100 U) had, on average, the greatest reductions in urinary incontinence episodes (UIE), urgency episodes, and micturition frequency, and the highest odds of achieving decreases of 100% and ≥50% from baseline in UIE/day. When comparing onabotulinumtoxinA with other pharmacotherapies, mean differences favoured onabotulinumtoxinA 100 U over all comparators for UIE and urgency episodes (credible intervals excluded zero) and all but two of the comparators for micturition frequency. OnabotulinumtoxinA 100 U was also associated with higher odds of achieving a 100% and ≥50% decrease in UIE/day than most other licensed treatments in the network. The exclusion of studies with a high risk of bias had little impact on the conclusions.
Conclusion
The results indicate that, after 12 weeks, onabotulinumtoxinA 100 U provides greater relief of OAB symptoms compared with most other licensed doses of other pharmacotherapies in the network.
Introduction
Overactive bladder (OAB) varies in degree of severity and may progress; in many patients the symptoms can be bothersome and have a negative impact on quality of life [1] . Several treatment options are available including bladder and behavioural training, pharmacological treatment, onabotulinumtoxinA, neuromodulation (sacral nerve simulation, percutaneous tibial nerve stimulation), and surgical therapies. Clinical guidelines recommend that OAB with urinary incontinence (UI) should be managed using a stepped approach, starting with conservative measures, e.g. lifestyle changes and behavioural therapies, as first-line therapy [2, 3] . These are followed by second-line treatments, e.g. anticholinergics or b 3 -adrenoceptor agonists, but both of these have been associated with poor persistence and adherence rates [4, 5] . For patients who are inadequately managed by first-and second-line treatments, clinicians can offer third-line options, e.g. intradetrusor onabotulinumtoxinA, sacral neuromodulation, and percutaneous tibial nerve stimulation [3] .
Given the range of different treatments available for OAB, it is sometimes difficult for a clinician to understand the relative effectiveness of these treatments. Direct head-tohead clinical trials would be one way of answering this question; however, study cost, study design, and other logistical issues create a barrier; thus, there is a paucity of this type of data. Network meta-analysis (NMA) is a statistical technique that provides a way to combine previously published clinical trials to compare treatments in lieu of doing a head-to-head trial. The objective of the present study was to use an exhaustive set of data, obtained by updating and combining previously conducted systematic reviews [6] [7] [8] , to evaluate the clinical efficacy of onabotulinumtoxinA, mirabegron (a b 3 -adrenoceptor agonist), and various anticholinergics in adults with idiopathic OAB with/without UI, through a mixed treatment comparison using NMA and network metaregression analysis (NMR). The appropriate Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed [9] .
Patients and Methods

Eligibility criteria
The eligibility of studies for inclusion in the NMA was established a priori and documented in a project protocol (Appendix S1). Eligible studies were blinded randomised controlled trials (RCTs), of ≥2-weeks duration, comparing any dose of onabotulinumtoxinA, mirabegron, or any of the eligible oral/transdermal anticholinergics, with each other or placebo, in adults with idiopathic OAB (Table 1) .
Study identification and selection
The search strategies for this update review were based on previously published reviews [7, 8] . The strategies and the resources searched were designed to meet the principles embodied in systematic review guidance from the Centre for Reviews and Dissemination (CRD) [10] and the Cochrane Collaboration [11] , and to meet the minimum resources specified in the National Institute for Health and Care Excellence specification for technology appraisal submissions [12] . An extensive search was conducted in nine electronic databases, relevant reviews and guidelines, websites, and abstract books from several major conferences, to identify any new relevant studies on onabotulinumtoxinA, mirabegron, or any of the eligible anticholinergics that might contribute to the NMA. To combine and expand upon the previous reviews [7, 8] , the searches were limited to cover only the period October 2007 to July-August 2014. Studies in all languages were sought, but only relevant studies reported in English were to be included in the analyses. Information resources searched and electronic search strategies for Medline and Embase are detailed in Appendix S2 (Table A1 ; appendices A1 and A2). The search strategies for other data sources are available on request.
Two independent reviewers (D.C. and A.L.) assessed the relevance of each record retrieved by the searches (Fig. 1) according to the review's eligibility criteria and any disagreements were resolved through discussion and/or by consulting a third reviewer (R.M.). Details of the studies excluded after examination of the full text, along with the reason for exclusion, are available on request. Where studies were reported in more than one publication they were grouped as associated references.
Data extraction and study assessment
One reviewer (D.C., A.L., R.M.) extracted data from the studies using a standardised data extraction form, whilst a second reviewer checked each extraction. Any disagreements were resolved by discussion or with the input of a third reviewer (D.C., A.L., R.M.). Key study characteristics relating to study methods, populations, trial settings, treatments, and outcomes were extracted to inform both the similarity assessment and the outcome analyses for the networks developed.
A preliminary series of theoretical networks was produced based on the interventions and comparators in each trial. Following the similarity assessment, the network for each outcome was adapted to reflect the trials that actually reported data for that outcome.
Advisory Committee (PBAC) [14] , detailed in Appendix S2 (Table B1 ). The quality of studies was also assessed, based on the quality criteria outlined in the Cochrane Assessment of Risk of Bias tool [11] . A summary assessment of risk within the trial was then formulated using the three main categories of risk ('low', 'unclear', 'high') suggested in the Cochrane approach, supplemented with two additional intermediate categories ('low/ unclear', 'some') (Appendix S2: Tables C1, C2 ).
Network development
Networks were developed for each outcome, based on the similarity of the trials and outcomes measures, and the data available. NMA were conducted using studies that were considered suitably homogeneous to facilitate reliable comparison, based on the quality of study methods, confounding factors (participants and circumstances), common treatment arms, and outcomes, as assessed by the modified PBAC tool (Appendix S2: Table B1 ), and reported sufficient data at 12 weeks. The outcomes of interest were: mean change in UI episodes (UIE)/day; proportions of patients achieving 100% and ≥50% reductions from baseline in UIE/day; mean change in urgency episodes/day; mean change in urgency UIE/day; mean change in the frequency of micturition/ day. • Patients with OAB and UI with a known cause (e.g., surgery, pregnancy, BPH, BOO);
• Neurogenic OAB;
• Stress UI*;
• Bladder oversensitivity or hypersensitivity;
• Mixed populations where results not reported separately for idiopathic OAB subgroup. Intervention
• Trospium.
• Combined therapies of the above with a non-pharmacological treatment if all treatment arms received the same nonpharmacological treatment.
• Other variants of botulinum toxin such as abobotulinumtoxinA.
• Flavoxate (on the market but rarely used in practice);
• Propantheline (not licensed for OAB);
• All intravesical anticholinergic formulations;
• Combinations e.g. anticholinergics + a-blocker.
Comparator
• OnabotulinumtoxinA; • Mirabegron; • Any of the specified oral/transdermal anticholinergics;
• Sham treatments; • Placebo; • Best supportive care.
Outcomes
• Change from baseline (number of episodes/day) in:
• Urinary frequency.
• Proportion of patients who achieve:
• • Retrospective studies.
*The term 'urinary incontinence' does not preclude stress UI, but studies of patients specifically with stress UI were excluded where reported.
† OnabotulinumtoxinA 100 U was the key dose of interest but studies evaluating other dosages could contribute to the evidence network where appropriate; in accordance with the study protocol, outcomes of interest were only assessed for onabotulinumtoxinA 100U. ‡ Immediate and extended release formulations. § Studies reported in languages other than English were sought but not included in the analyses.
Heterogeneity assessment
For all of the outcomes, heterogeneity was assessed for each pairwise comparison (that was informed by at least two trials) by calculating the I 2 statistic. I 2 values of <25% are considered to indicate little to no heterogeneity, while 'substantial' heterogeneity is represented by an I 2 value of 50-90% [11] . The assessment of heterogeneity was conducted using the R package 'meta' [15] .
Statistical methods
For continuous outcomes, NMR was conducted in lieu of a standard NMA in order to adjust for differences in the baseline levels of each outcome variable between studies. The NMR model was adapted from the model proposed by Owen et al. [16] -a three-level hierarchical Bayesian NMA, with the addition of baseline severity as a covariate. For the binary outcomes, NMA [17] was chosen over NMR, as exploratory analyses based on individual patient data from two onabotulinumtoxinA trials [18, 19] showed no significant evidence that the baseline number of UIE was associated with the treatment effect odds ratios for a 100% or ≥50% reduction in UIE.
Random-effects models were chosen a priori for both NMRs and NMAs, as they allow for heterogeneity in the treatment effects between studies and provide wider, more conservative, credible intervals (CrIs). In addition, based on the work of Owen et al. [16] , the models made two further assumptions: treatments within each class (i.e. anticholinergics, onabotulinumtoxinA, and mirabegron) have similar efficacy; higher doses of the same treatment are more effective than lower doses. In the absence of any robust evidence to the contrary, we also assumed no difference in efficacy between the placebo treatments, i.e. they would be equally effective in similar populations.
Two analyses were planned for each outcome network: one which included all studies and one which excluded studies considered to have a high risk of bias (RoB), based on the Cochrane Risk of Bias tool. All analyses were conducted using WinBUGS version 1.4.3 [20] and R version 3.0.1 [21] . For each outcome, consistency was evaluated by comparing the fit of the standard model to the fit of an inconsistency model [22] . Model fit was measured by the deviance information criterion. Further details of the statistical analyses are provided in Appendix S2 (appendix D1).
Relative treatment effects are summarised by point estimates and 95% CrIs, which are the Bayesian analogue of confidence intervals. For continuous outcomes (i.e. mean difference), CrI that exclude zero suggest a difference between treatments; for binomial outcomes (i.e. odds ratio), CrI that exclude '1' suggest a difference between treatments. Estimates from the NMA are presented in the form of forest plots for both binary and continuous outcomes.
Results
Included studies
The update searches identified 4408 records. These were combined with the search results for the original review [8] and the records of studies included in the Chapple et al. [7] review, and duplicate data subsequently removed. The overall search process yielded 4679 records ( Fig. 1 ). Of these, 102 studies (reported in 323 publications) met the inclusion criteria (Appendix S3: Table A ) and provided data on at least one of the outcomes of interest: 10 studies assessed onabotulinumtoxinA, 10 studies assessed mirabegron, 90 studies assessed the specified oral/transdermal anticholinergics (three darifenacin, 13 fesoterodine, 28 oxybutynin, 12 propiverine, 16 solifenacin, 36 tolterodine, and five trospium).
Similarity assessment
Key characteristics relating to study methods, populations, trial settings, and treatments were considered within the similarity assessment. Study characteristics, according to intervention, and the RoB assessment are summarised in Appendix S3 (Tables B1, C1 ). Although the trials were broadly similar in terms of their methodology, populations, and outcomes, potential sources of heterogeneity were identified that could affect their inclusion in a mixed treatment comparison; these are shown in Table 2 and further detailed in Appendix S3 (appendix B).
Study methods and patient baseline characteristics were not reported or described in sufficient detail for many of the trials included in the review, and there was wide variation across studies in treatment duration and the baseline severity of the patients' symptoms (Appendix S3: Tables B1,B2 ). To reduce heterogeneity networks were limited to those studies reporting data for each outcome at 12 weeks, as this is the most common time point for reporting the effects of OAB treatments [23] . Baseline severity (i.e. baseline number of events) was found to be a treatment effect modifier in the previous review [8] . Thus, for continuous outcomes, a random-effects NMR was applied to adjust for differences in the baseline levels of each outcome between studies. However, an NMA could be conducted for 100% and ≥50% reduction in UIE, as an exploratory analysis based on individual patient level data found no significant evidence that baseline severity impacted treatment effect for these outcomes (Appendix S2: appendix D1). There were also notable differences between studies of each specific intervention in terms of drug formulation and dosage (Appendix S3: Table B3 ). It was assumed that different formulations and/or dosages may have different efficacy and hence the network includes a separate node for each combination of intervention, formulation, and dosage.
Possible networks
Following the similarity assessment, several key decisions were made that resulted in 46 studies being excluded from the network analysis. Most of the studies were excluded due to a lack of reporting; 29 studies did not report relevant data at 12 weeks, and seven studies did not report sufficient data for any of the outcomes of interest. The reasons for exclusion are detailed further in Appendix S3 (Table D1 ). In all, 56 studies (reflecting 37 treatments including placebo) were therefore considered similar enough in terms of key criteria and reported sufficient data to contribute to an NMA or NMR for one or more of the outcomes of interest. Two networks were explored for each outcome; a primary network including all studies with sufficient data (regardless of RoB), and a sensitivity analysis which excluded trials deemed to have a high risk of bias. Of the 56 studies included in the network analyses 22 had a high RoB, 26 had some RoB, and the RoB was unclear in eight studies. The size and complexity of the network diagrams differed depending on the data reported in each trial, thus the number of trials and treatments evaluated were different for each individual outcome network (Appendix S3: Table D2 ). Figure 2 shows the simplified networks; the individual network diagrams for each outcome are presented in Appendix S3 (Figs D1-D6).
Assessments of heterogeneity and inconsistency
Heterogeneity was assessed for each pairwise comparison that was informed by more than one trial. For both the primary networks and the sensitivity analysis excluding studies with a high RoB, most pairwise comparisons exhibited little to no heterogeneity (I 2 <25%), indicating that the results were similar across all studies. Comparisons exhibiting 'substantial' heterogeneity, represented by an I 2 value of 50-90% as described in the Cochrane Handbook [11] are summarised in Appendix S3 (Table E1 ). For each of the outcomes, there was no evidence of inconsistency.
NMA
Results for the objective measures of change in UIE, urgency episodes, micturition frequency, and 100% and ≥50% reduction in daily UIE are reported here. Urgency UIE is a subjective measure that is based on patient questionnaires and is determined by various threshold on those questionnaires to rate the urgency level of a particular UIE. Only a few studies defined urgency UI and even among those studies there was a great variety of questionnaires and thresholds used. This failure to define the outcome, coupled with discrepancies between studies where the outcome was defined, makes NMA unreliable. For these reasons, results for urgency UIE are not reported here. Individual outcome networks comprised seven to 53 studies, corresponding to nine to 36 treatments (Appendix S3: Table D2 ). Results of random-effects models are presented for licensed treatments only, although studies of both licensed and unlicensed doses could contribute to the networks. Figures 3 and 4 provide detailed forest plots of estimates from the NMA for the primary analysis with all studies included in each outcome network, including titrated doses. All outcomes were analysed at 12 weeks.
After the exclusion of studies considered to have a high RoB, individual outcome networks comprised 5-32 studies (six to 27 treatments) (Appendix S3: Table D2 ). Forest plots detailing the results of the sensitivity analyses for outcomes analysed at 12 weeks are presented in Appendix S3 (appendices F1and F2).
OAB treatments vs placebo
Primary analysis
For each NMR, the relative treatment effects are based on patients with average baseline values of the outcome (UIE 3.2 episodes/day; urgency 7.6 episodes/day; micturitions 11.7 episodes/day). The results suggest that all licensed treatments are more efficacious than placebo in reducing UIE, urgency episodes, and micturition frequency (Fig. 3) . After 12 weeks of treatment, patients receiving onabotulinumtoxinA 100 U have, on average, the greatest reductions in UI, urgency, and micturition compared with placebo: reductions of 1.55 UIE more per day (CrI 1.10-2.01), 2.01 urgency episodes more per day (CrI 1.48-2.54), and 1.37 micturitions more per day (CrI 1.03-1.70). Compared with placebo, there was evidence that all licensed treatments in the network were associated with higher odds of having a decrease in daily UIE of 100% (Fig. 3) . In addition, the results suggest that patients receiving onabotulinumtoxinA 100 U have the highest odds of achieving reduction of 100% and ≥50% in the number of UIE/day [odds ratios relative to placebo: 4.30 (CrI 3.03-6.23) and 3.43 (CrI 2.51-4.68)]. The removal of studies considered to have a high RoB had little effect on the results of the primary analysis (Appendix S3: appendix F1).
Anticholinergics and mirabegron vs onabotulinumtoxinA
Primary analysis
The NMR indicated that treatment with onabotulinumtoxinA (100 U) resulted in greater mean reductions in UIE and urgency episodes compared with all of the other licensed pharmacotherapies included in the network (all point estimates and CrIs favoured onabotulinumtoxinA 100 U). For micturition frequency, onabotulinumtoxinA 100 U was superior to most of the licensed oral treatments. There was no evidence of a difference between onabotulinumtoxinA 100 U and the other two most effective licensed doses [solifenacin 10 mg once daily (QD) and oxybutynin controlled-release 10 mg QD]. The results of the NMA suggested that onabotulinumtoxinA 100 U was associated with a higher odds of achieving a 100% decrease in the number of UIE/day • Predominantly double blind for the assessed treatment period;
• Duration of treatment period;
• Patient losses or withdrawals.
• Wholly or predominantly female populations;
• Similar mean ages BUT some studies recruited specific age groups;
• Patients had received various prior treatments -few restrictions placed on prior therapy in the eligibility of studies;
• Severity of condition at baseline;
• Concomitant therapies.
• Doses, administration and scheduling were not similar between studies for most interventions.
*Bold text indicate important sources of heterogeneity based on details reported in the individual studies.
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© 2017 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International after 12 weeks than all other licensed treatments in the network, and a higher odds than most other treatments for a ≥ 50% reduction in daily UIE; there was no evidence of a difference between onabotulinumtoxinA 100 U and darifenacin 15 mg QD for a decrease of ≥50% in daily UIE. Figure 4 shows the forest plots detailing all of the results. The removal of studies considered to have a high RoB had little effect on the results of the primary analysis (Appendix S3: appendix F2).
Discussion
The present review combined all relevant evidence available on the efficacy of treatment of adults with OAB, with/without UI, using any doses of onabotulinumtoxinA, mirabegron, and oral/transdermal anticholinergics. In the absence of direct comparative evidence, the relative efficacy of licensed doses of treatments for OAB was evaluated through a mixed treatment comparison using NMA. NMR was used for continuous outcomes, to account for differences between baseline OAB severities among the studies.
Five efficacy outcomes were assessed, with each network including between seven and 53 studies (corresponding to nine to 36 unique treatment regimens). Only studies reporting relevant data at 12 weeks were included in the networks, as this is the most common time point for reporting the effects of OAB treatments [23] . Sensitivity analyses were also conducted to assess the effect of excluding studies considered to have a high RoB.
Results from the NMR/NMA suggest that all treatments are more efficacious than placebo in improving OAB symptoms measured in terms of UIE/day, 100% and ≥50% reductions in UIE, urgency episodes, or micturition frequency after 12 weeks. OnabotulinumtoxinA showed the greatest reductions in all these OAB symptoms. When comparing active treatments with each other, patients receiving onabotulinumtoxinA 100 U had the greatest mean reductions in UIE, urgency, and micturition, and the highest odds of 100% and ≥50% decreases in daily UIE, compared with most of the pharmacological treatments (licensed doses) included in the networks. The exclusion of studies considered at high RoB generally had little or no impact on the overall findings of improved OAB symptoms with onabotulinumtoxinA 100 U compared with anticholinergics and mirabegron.
OnabotulinumtoxinA, mirabegron, and anticholinergics all have acceptable, albeit different safety profiles [24] . The adverse effects of anticholinergic drugs are well documented and commonly include dry mouth and constipation [25] . Tachycardia, UTI, nausea, constipation, diarrhoea, headache, and dizziness may be associated with mirabegron treatment [26] . Side-effects associated with onabotulinumtoxinA are UTI, bacteriuria, urinary retention, and increased residual urine volume, in addition to procedure-related adverse reactions, e.g. dysuria and haematuria [27, 28] . A high incidence of sideeffects or intolerable side-effects will most likely contribute to discontinuation of treatment, in particular for patients on long-term medication. After 12 months, persistence rates based on prescription data are low: 14-35% for antimuscarinic agents in the UK [29] ; 14-22% for antimuscarinics and 31.7% for mirabegron in Canada [4] ; and 18% for OAB medications in the USA [5] . The 2-year data from a large retrospective cohort study showed that 51.3% of patients had permanently discontinued anticholinergic treatment by the end of 2 years, with most discontinuations occurring in the first 6 months [30] . In contrast, discontinuation rates observed within the trial setting of the studies included in the systematic review were low: 0-18% for onabotulinumtoxinA, 10-24% for mirabegron, and 3-38% for anticholinergics, when reported. Currently, there is limited evidence comparing the safety of onabotulinumtoxinA, mirabegron, and anticholinergics. Chancellor et al. [30] particularly noted a paucity of research exploring treatment patterns beyond use of first anticholinergic. Although we recognise the negative impact side-effects will have on health-related quality of life and in adherence and persistence with treatment, the present analysis focused on efficacy outcomes that were the most uniformly reported in the literature. Hence, it did not investigate adverse events or patient-reported outcomes across the treatments, as these were not outcomes that were pre-specified in the protocol and as such these data were not extracted. This represents a limitation of the review.
NMA, like pairwise meta-analysis, is subject to limitations such as the varying quality of the individual studies and publication biases. A key consideration for any NMA is whether the identified studies are similar enough to facilitate reliable comparison for each outcome of interest. Flaws in the design, conduct, and analysis of RCTs can also lead to bias and raise questions about the validity of their findings. In the present review, the candidate studies were judged to be broadly similar in terms of key study characteristics (methodological quality, patient populations, treatments, and outcome measures). However, poor reporting of study methodology hampers our assessment of the similarity of studies and also their degree of bias. Precision may suffer by the inclusion of only studies classified as low RoB due to paucity of data. The sensitivity analysis we undertook showed no impact on the results of the NMA when excluding studies considered to have a high RoB. The populations studied in the included RCTs were wholly or predominantly female (where reported, all but two studies were >65% female). In the absence of any published evidence suggesting otherwise, the present network analysis has assumed that gender does not affect response to treatment. Across studies of each intervention there was wide variation in the patients' baseline number of UIE, urgency episodes, and micturition frequency, which may reflect differences in outcome assessment. In addition, onabotulinumtoxinA is licensed for use after anticholinergic failure, thus patients included in these trials would be expected to have more severe symptoms. As differences in baseline severity have been found to modify the treatment effect [8] , we applied an NMR model. We assumed that all active treatments across the three classes (onabotulinumtoxinA, mirabegron, and anticholinergics) have the same relationship between baseline severity and change from baseline, as continuous baseline severity was not found to impact 100% or ≥50% reduction in UIE. An NMA for these outcomes was conducted. A recent analysis of 100% reduction in UIE/day suggested a trend for an increasing treatment effect with increasing categorical baseline UI severity; however, this relationship was not statistically significant (Drake et al. EAU 30th Annual Congress; 20-24 March 2015; Madrid, Spain).
We also made assumptions in relation to the treatments that should be taken into account when considering the validity of the model and results of the analyses. The large number of unique treatments (maximum 37) and relatively few trials (seven to 53) included in the outcome networks can lead to uncertainty in the treatment effect estimates. To reduce this uncertainty we adapted the methods of Owen et al. [16] , incorporating an assumption in the model that higher doses of a treatment are more effective than lower doses, and treatments within a class (onabotulinumtoxinA, mirabegron, and anticholinergics) share similar efficacy. In addition, the treatments differed in their mode of administration. In the onabotulinumtoxinA trials, placebo was administered as a single injection, while in the mirabegron and anticholinergics trials, the placebos were administered as daily oral tablets, transdermal patches or gels. In order to connect the network, we have made the assumption that the different placebo treatments would be equally effective when administered to the same populations [13] . However, in the light of a recent meta-analysis [31] , which has shown differential placebo effects to impact the estimates of relative efficacies of active treatments for knee osteoarthritis, this is an area that would benefit from further research.
The present updated review and NMA was informed by extensive searches in a range of databases and websites of key regulatory bodies to ensure that as many relevant studies as possible were identified and assessed for relevance to the review question. However, only studies published in English were reviewed in full due to resource constraints; this means that the review may be subject to some publication bias. Systematic reviews suggest that studies reporting a 'positive' result are both more likely to be published and also more likely to be published in English [32, 33] . The impact of potential publication bias was not explored in the present review.
OnabotulinumtoxinA and mirabegron are relatively new treatments that have only recently gained marketing authorisations for the treatment of OAB, whereas anticholinergic drugs have been available for many years and their use in clinical practice is widespread. Although the efficacy and safety of these treatment types are well documented in the literature, few studies have sought to establish their relative treatment effects. Consistent with our present findings, three systematic reviews found mirabegron had similar efficacy to most antimuscarinics [34] [35] [36] and, where studied, all were more efficacious than placebo in reducing the frequency of UI and micturitions [35, 36] . In contrast, another meta-analysis showed mirabegron to be more effective than tolterodine in the number of UIE/day, but not for micturition frequency [37] . A systematic review of non-antimuscarinic treatments for OAB, including lifestyle changes, found only one study each of onabotulinumtoxinA and mirabegron compared with active treatment [38] . A Cochrane review that compared the effectiveness of intravesical botulinum toxin with other treatments for neurogenic and idiopathic OAB failed to identify any relevant studies that compared botulinum toxin with mirabegron or anticholinergics [39] .
To the best of our knowledge, the present mixed treatment comparison represents the most up-to-date evaluation of the relative efficacy of onabotulinumtoxinA, mirabegron, and anticholinergics. Owen et al. [16] have evaluated the change from baseline in UIE and the number of patients reporting at least one adverse event in an NMA of treatments for OAB; changes from baseline in frequency and urgency have been presented in conference posters [Owen et For the change from baseline outcomes, our present NMA also adjusts for the important issue of differences in baseline severity.
The present mixed treatment comparison adds valuable information to the evidence base on the comparative effectiveness of treatments for OAB to assist in the treatment selection process. Future research building upon these existing networks with other treatments for OAB aside from monotherapy, such as mirabegron add-on therapy as assessed in the BESIDE study [40, 41] , is ongoing, and several systematic reviews/NMA of pharmacological treatments for OAB have been registered on PROSPERO (International prospective register of systematic reviews).
Conclusions and future research
In the absence of head-to-head trials between onabotulinumtoxinA, anticholinergics, and mirabegron, the present mixed treatment comparison represents the best available comparative analysis of anticholinergics, mirabegron, and onabotulinumtoxinA. After 12 weeks of treatment, onabotulinumtoxinA (100 U) was associated with the greatest reductions in UIE, urgency episodes, micturition frequency, and the highest odds of achieving 100% and ≥50% reductions in UIE compared with all other licensed treatments in the network. In addition, onabotulinumtoxinA 100 U provided greater relief of OAB symptoms compared with most other licensed doses of anticholinergics and mirabegron in the network. There is a need for more supporting evidence from well-designed and conducted head-to-head trials that assess efficacy outcomes and adverse events over similar time periods using similar measures. Such trials should also investigate factors affecting adherence and persistence: an understanding of why these are so low may help identify specific patient needs that require attention and could result in improved quality of life for these patients.
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